Deepa Pakianathan is a Managing Member at Delphi Ventures and the CEO of Redd Pharmaceuticals. She currently serves on the board of Calithera Biosciences where she is lead director, as well as Karyopharm Therapeutics, Mereo BioPharma Group plc, Thervance Biopharma and FSDC Corp. She serves as Executive vice-chair and Treasurer on the San Francisco Conservatory of Music’s Board of Trustees.
While at Delphi, Pakianathan has funded 11 drugs that are on the market helping patients including three that generate over $1 billion in revenue each.
Pakianathan joined Delphi in 2001 to build and lead the firm’s biotechnology investment practice. Prior to joining Delphi, Pakianathan was an M&A and corporate finance banker in the healthcare group at J.P. Morgan. Prior to that, she was a biotechnology research analyst at Genesis Merchant Group. She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997. Pakianathan received her Ph.D. and MS from Wake Forest University and her MSc and BSc from the University of Bombay.